With EBV+ AIDS-DLBCL patients continuing to face poorer outcomes compared to EBV- AIDS-DLBCL patients despite antiretroviral therapy and advanced chemotherapeutic regimens [42,43], targeting ZC3H18 alongside EBNA1 (or STAT3) may offer greater benefit. This evidence concerns the gene STAT3 and diffuse large B-cell lymphoma.